Publications by Dr. LaMarca
Effect of continuous growth hormone therapy on lean body mass (LBM) and AIDS-defining events in HIV-
associated wasting (HIV-W).
Daar ES; LaMarca A; Schambelan M; Grunfeld C; Mulligan K; Breitmeyer J
3rd ConfRetro and Opportun Infect. 1996 Jan 28-Feb 1;:125.
NLM Citation ID: 96920388
A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium aviun complex infection in
patients with advanced acquired immunodeficiency syndrome [see comments]
Pierce M; Crampton S; Henry D; Heffets L; LaMarca A; Montecalvo M; Wormser GP; Jablonowski H; Jemsek J;
Cynamon M; Yangco BG; Notario (3; Craft JC
N EngI J Med. 1996 Aug 8;335(6):384-91.
NLM Citation ID: 96293368
Recombinant human growth hormone (rhGH) increases lean body mass (LBM) and improves functional performance
in patients with HIV-associated wasting.
Schambelan M; Mulligan K; Grunfeld C; Daar E; LaMarca A; Breitmeyer J
Nati Conf Hum Retroviruses Relat Infect (2nd). 1995 Jan 29-Feb 2;: 170.
NLM Citation ID: 95920649
Growth hormone therapy of AIDS wasting.
LaMarca A; Schambelan M; Mulligan K; Grunfeld C; Kennedy S; Breitmeyer J; Daar E
Int Conf AIDS. 1994 Aug 7-12;l0(2):35 (abstract no. 432B).
NLM Citation ID: 94372089
Clinical manifestations of M. avium complex (MAC) bacterernia in patients with AIDS. Liiifabutin Study Group.
LaMarca A; Siegal FP; Chaisson R; Stern J; Bernstein B; Matthew B; Havlik J; Scheibel S; Thompson M; Bianchine
J; etal
Int Conf AIDS. 1992 Jul 19-24;8(2):B129 (abstract no. PoB 3256).
NLM Citation ID: 92400984
Effect of continuous growth hormone therapy on lean body mass (LBM) and AID S-defining events in HJV-
associated wasting (HIV-W).
Daar ES; LaMarca A; Schambelan M; Grunfeld C; Mulligan K; Breitmeyer J
3rd ConfRetro and Opportun Infect. 1996 Jan 28-Feb 1;: 125.
NLM Citation ID: 96920388
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
Markowitz M; Saag M; Powderly WG; Hurley AM; Hsu A; Valdes JM; Henry D; Sattler F; La Marca A;
Leonard JM; et al
N Engl J Med. 1995 Dec 7;333(23):1534-9.
NLM Citation ID: 96067436
Clinical efficacy of Stavudine compared to Zidovudine in HIV-infected Zidovudine-experienced patents.
Spotswood S; Pavia A; LaMarca A; Mellors J; Murphy R; Gathe J
8th Int Soc Antiv Resh, 1995 April 23-28
Clinical efficacy of Stavudine compared to Zidovudine in HIV-infected Zidovudine-experienced patents.
Spotswood S; Pavia A; LaMarca A; Mellors J; Murphy R; Gathe J
N Engl J Med 1995 Oct 23
A master protocol to evaluate the safety and efficacy of multidrug combination antiretroviral therapy with
Zidovudine and Zalcitabine with or without Saquinavir or Nevirapine for the treatment of HIV infection.
Thompson M; Myers M; Salgo M; LaMarca A.; Roussear F.; Odorisio M
4th Conf Retro and Opportun Infect. 1997 Jan 22-26
Short duration oral Terbinafine in the treatment of Tinea Pedis in HIV-positive patients.
Smith S; Houpt K; Rich P; LaMarca A; Weinberg J; Alferez T; Opper C; Atillasoy E
Churchill Comm 2000 Dec 20
The combination of topical Alitretinoin Gel plus Liposomal Doxorubicin appears safe and effective as treatment of
AIDS-related Cutaneous Kaposi’s Sarcoma.
LaMarca A; Miller B; Conant M; Eden C; Stevens V
AAD meeting 2002… Reuters Health. OncoLink 27th February 2002
Natural History of Anemia Associated with Interferon/Ribavirin (IFN/RBV Therapy for HIV/HCV Coinfected
Patients.
Dr. Henry, Joan Karnell Cancer Ctr, Pennsylvania Hosp., Philadelphia, PA; L. Lambiase, Univ. of Florida,
Jacksonville, FL; G, Pierone, Treasure Coast Infectious Dis Cons., Vero Beach, FL; W. Woodward, Bornemann Int.
Med., Reading, PA; J. Slim, St. Michael’s Med Ctr., Newark, N.J; A. LaMarca, Therafirst Med. Ctr., Fort
Lauderdale, FL; M. Hoffman-Terry, Lehigh Valley Hosp., Allentown, PA; P. Bowers, Johnson & Johnson
Pharmaceutical R & D, Raritan, N.J.; G. Leitz, Ortho Biotech Products, L.P., Bridgewater, NJ for the HIV/HCV Co-
infection Natural History Group.
Efficacy and Safety of a once daily (OAD) Fixed-Dose Combination (FDC) of abacavir/lamivudine ABC/3TC [FDC
arm] versus ABC twice daily (BID) and 3TC OAD as separate entities [SE arm] in ART-Experienced HIV-1 Infected
Subjects: 48 week
1 A.LaMarca, 2. K Fu, D.Gordon,3. C. Craig, 3. H.Zhao, 3.D. Paes,3. T. Scott.3.
1. Therafirst Medical Ctr., Fort Lauderdale, Fl. 2. GlaxoSmithKline
Efficacy and Safety of a once daily (OAD) Fixed-Dose Combination (FDC) of abacavir/lamivudine ABC/3TC [FDC
arm] versus ABC twice daily (BID) and 3TC OAD as separate entities [SE arm] in ART-Experienced HIV-1 Infected
Subjects: (CAL30001) (Clinical Science, volume 41, Number 5, April 15 2006).
LaMarca, Anthony. M.D; Clumeck, Nathan m.D., Ph.D; Plettenberg, Andreas M.D, Ph.D;
Domingo, Pere M.D, Ph.D; Fu, Kaisong. M.D, Ph.D; Craig, Charles Ph.D; Zhao, Henry Ph.D; Watson, Maria Ph.D;
Gordon, David MB,ChB, Scott, Trevor Ph.D. on behalf of the CAL30001 study team.
Therafirst Medical , Fort Lauderdale FL; CHU Saint-Pierre, Bruxelles, Belguim; Institut fuer Inderdisziplinaere
Infektiologie und Immunologie GmbH, Hamburg, Germany; Hospital Sant Greu y Sant Paublo, Barcelona, Spain
;GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Stevenage, UK;
GlaxoSmithKline, Greenford, U.K.
A randomized study of emtricibine and lamivudine in stably suppressed patients with HIV
Constance A. Benson, Charles van der Horst, Anthony LaMarca, David W. Haas, Cheryl K. McDonald, Corklin R.
Steinhart. John Rublein, Joseph Quinn, Elsa Mondou, Frank Rousseau and FTC-303/350 Writing Group.
Aids2004, 18:2269-2276.
ISSN 0269-9370 - 2004
ACTION Study: Efficacy and safety of Trizivir (TRV) BID Versus Combivir (COM) BID + Atazanavir (ATV) QD
in ART-Naïve HIV-! Infected Subjects.
P.Kumar, P.Patel, P.Salvato, E.DeJesus. A.LaMarca, A. Florance, D.McCleron, P.Wannamaker and m.Shaefer,
georgeTown University, Washington. D.C., GlaxoSmithKline, RTP, N.C., Diversified Medical Practice, Houston,
TX., Orlando Immunology Center, Orlando, FL., Therafirst Medical Centers, Inc, Fort Lauderdale, FL.
2005
Antiviral Activity and Safety of Aplaviroc a CCR5 Antagonist in Combination with Lopinavir/Ritonavir in HIV-
Infected therapy Naïve Subjects.
Patrick Yeni. M.D. Anthony LaMarca. M.D., Daniel Berger. M.D. Paul Cimoch. M.D. FACP, Prof. Adriano
Lazzarin, Patricia Salvato. M.D. Fiona Smaill, M.D. Eugenio Teofilo, M.D. Sam Madison, MSc. Garret Nichols.
M.D., Deb McCarty, Kimberely K. Adkinson, Ph.D.,Tab Bonny. MS. Judith Millard. Ph.D., and the EPIC
(CCR100136) team .
University Hospital Bichat, Paris. Bonn , Therafirst Medical Centers, Fort Lauderdale, Florida. United States. North
Star Medical Center, Chicago, IL, Center for Special Immunology, Fountain Valley, CA, Division Malattie Infettive,
Milano, Otaly, Diversified Medical Practices, Houston, TX, Hamilton Heath Services, Ontario, Canada,Centro
Hospitalar de Lisboa, Lisbon, Portugal, GSK, Research Triangle Park, NC, United States and GSK, Greenford,
United Kingdom, W.L.Gore and Associates, Flagstaff, AZ.
Low Incidence of Drug Resistance after Virologic Failure in HIV-1 Infected Subjects Randomized to Remain on their
Current Protease Inhibitor (PI) or switched to Fosamprenavir (FPV) regimen for 24 weeks.
Ross L. GlaxoSmithKline, Research Triangle Park, NC., Young, B. Denver ID Consultants, Denver, CO.,
DeJesus, E. Orlando Immunology Center, Orlando, FL., LaMarca, A. Therafirst Medical Centers, Fort Lauderdale,
FL.,Salvato,P., Williams, V., Balu, R., Shaefer, M.S. Diversified Medical Practices, Houston, TX.
[P394] Safety and Antiviral activity of the Novel CCR Antagonist Aplaviroc in Combination with
Lopinavir/Ritonavir in HIV-Infected naïve subjects.
Patrick Yeni, Anthony LaMarca. Sam Madison, Garret Nichols, Judith Millard, Deb McCarty, Tab Bonny, The Epic
Study Team.
University Hospital Bichat, Paris France: Therafirst Medical Centers, Fort Lauderdale, Florida, USA:
GSK, RTP, NC, USA: GSK Greenford, UK:.
Int Congress Drug Therapy HIV2006 Nov12-16:8 Abstract No. P394
Response to HIV Antiviral Therapy by Index Partner Pairs or Patients (Pts) Infected with a Genotypically
Homologous Strain of HIV Seeking Treatment with the Same ART.
D.H.Sutherland, E.Jesus, M.Potter, A.LaMarca, N.Bellos, J.Morales-Ramierez, I.Meldelez-Rivera, D.Ward, W.
Rashbaum, C.Newman, L.G. Patel, J.Horton and L.L. Ross for the Aries Study.
GlaxoSmithKline, RTP, NC, USA. Orlando Immunology Cntr, Orlando, FL, USA. Southwwest MUHC, Montreal,
QC, CN. Therafirst Medical Centers, Fort Lauderdale, FL. USA. Southwest Infectious Disease Assoc, Dallas, TX.
USA. Clin Res. San Juan, PR, USA. Capital Med Assoc, Washington, DC.USA. Med Col of Georgia, Augusta, GA.
USA.
Therafirst Medical Center
